These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14985722)

  • 1. Labs urged to pre-empt bioterrorism threat.
    Check E
    Nature; 2004 Feb; 427(6977):767. PubMed ID: 14985722
    [No Abstract]   [Full Text] [Related]  

  • 2. Groundbreaking research.
    Gewin V
    Nature; 2002 Nov; 420(6914):4-6. PubMed ID: 12459740
    [No Abstract]   [Full Text] [Related]  

  • 3. US to safeguard 'dual-use' biology research.
    Fox JL
    Nat Biotechnol; 2004 Apr; 22(4):369. PubMed ID: 15060540
    [No Abstract]   [Full Text] [Related]  

  • 4. Science and government. Biosecurity and research: minimizing adverse impacts.
    Gaudioso J; Salerno RM
    Science; 2004 Apr; 304(5671):687. PubMed ID: 15118148
    [No Abstract]   [Full Text] [Related]  

  • 5. The burgeoning science of genetics and the impact on public policy.
    Hatch OG
    J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US officials urge biologists to vet publications for bioterror risk.
    Check E
    Nature; 2003 Jan; 421(6920):197. PubMed ID: 12529597
    [No Abstract]   [Full Text] [Related]  

  • 7. The threat of bioterrorism.
    Graham B; Talent J
    Disaster Med Public Health Prep; 2011 Sep; 5 Suppl 2():S170-1. PubMed ID: 21908693
    [No Abstract]   [Full Text] [Related]  

  • 8. The view from the top.
    Howard K
    Nature; 2003 Dec; 426(6967):696-7. PubMed ID: 14668873
    [No Abstract]   [Full Text] [Related]  

  • 9. US biodefense contracts continue to lure biotechs.
    Shaffer C
    Nat Biotechnol; 2010 Mar; 28(3):187-8. PubMed ID: 20212465
    [No Abstract]   [Full Text] [Related]  

  • 10. The patentability of antibodies in the United States.
    Lu DL; Collison AM; Kowalski TJ
    Nat Biotechnol; 2005 Sep; 23(9):1079-80. PubMed ID: 16151395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost/success projections for US biodefense countermeasure development.
    Matheny J; Mair M; Smith B
    Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech as Bush bows out.
    Lorenzo A
    Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotech firms pin hopes on defence.
    Pearson H
    Nature; 2003 Apr; 422(6934):790. PubMed ID: 12712154
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 15. US federal bureaucracy hampers progress in countering bioterrorism.
    Fox JL
    Nat Biotechnol; 2002 Jun; 20(6):530. PubMed ID: 12042838
    [No Abstract]   [Full Text] [Related]  

  • 16. Patent drop reveals pressures on industry.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):930-1. PubMed ID: 15286630
    [No Abstract]   [Full Text] [Related]  

  • 17. Boston locals fight government scheme for bioterror defence lab.
    Dalton R
    Nature; 2004 Apr; 428(6985):785. PubMed ID: 15103335
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotech patenting slows in 2004.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1198. PubMed ID: 16211048
    [No Abstract]   [Full Text] [Related]  

  • 19. Taking the measure of countermeasures: leaders' views on the nation's capacity to develop biodefense countermeasures.
    Gilfillan L; Smith BT; Inglesby TV; Kodukula K; Schuler A; Lister M; O'Toole T
    Biosecur Bioterror; 2004; 2(4):320-7. PubMed ID: 15650441
    [No Abstract]   [Full Text] [Related]  

  • 20. Congress grills officials over biosafety boom.
    Callaway E
    Nature; 2007 Oct; 449(7163):646-7. PubMed ID: 17968389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.